Clinical trials: Breathing, Mouth
Mountain Sickness
Safety Evaluation of Aminophylline and Methazolamide
This safety study is the first in a series of studies testing the application of the combination of aminophylline and methazolamide.
- Trial name
- NCT01587027
- Testing
- Aminophylline, Methazolamide, Aminophylline and Methazolamide
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Poudre Valley Health System
Pulmonary Disease, Chronic Obstructive
Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease II
The primary objective of this study is to assess the long-term efficacy and safety of once daily treatment of BI 1744 CL inhalation solution (5 and 10 mcg) delivered via the Respimat® inhaler, in patients with COPD.
- Trial name
- NCT00796653
- Testing
- Olodaterol (BI 1744), Formoterol
- Where
- 98 sites in Argentina, Brazil and 18 more
- Volunteers
- 937 people
- Sponsor
- Boehringer Ingelheim
Xerostomia Following Radiotherapy, Xerostomia Following in Neck or Head After Cancer Surgery
Does Craniosacraltherapy Combined With Exercises That Focuses om Respiration and Posture in the Upper Body Have an Effect on Xerostomia and Other Late Sequelae on People Who Has Been Suffering From Cancer in Mouth and Throat?
The current study aims to assess the efficacy of manual treatment with craniosacral therapy of fascial tissue in throat, neck, cranial and mouth region, on radiation and/or surgery-induced salivary gland hypofunction and…
- Conditions
- Xerostomia Following Radiotherapy, Xerostomia Following in Neck or Head After Cancer Surgery, Other Late Sequelae Following Radiotherapy and Cancer Surgery in Neck or Head
- Trial name
- NCT05882890
- Testing
- Craniosacral Therapy, Exercices Targeting Upper Posture and Respiration
- Where
- 2 sites in Denmark
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Cathrine Rahbek
Exercise-induced Bronchoconstriction (EIB)
The Effect of Montelukast on Difficulty in Breathing After Exercise in Pediatric Patients (MK0476-377)(COMPLETED)
This study will see if there is a change in breathing after exercising when the child receives study drug ( montelukast or placebo).
- Trial name
- NCT00534976
- Testing
- Comparator: montelukast sodium
- Volunteers
- 364 people
- Sponsor
- Organon and Co
Asthma
Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices
This study assessed the efficacy, safety, tolerability, and pharmacokinetics of two different formulations of indacaterol, one administered via the Concept1 device and one administered via the Simoon device.
- Trial name
- NCT01012739
- Testing
- Indacaterol 150 μg via the Concept1 dry-powder inhaler, Indacaterol 60 μg via the Simoon dry-powder inhaler, Indacaterol 120 μg via the Simoon dry-powder inhaler
- Where
- 4 sites in Germany, Netherlands and 1 more
- Volunteers
- 35 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and ability of several doses of an orally inhaled medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to improve airflow in the lungs when delivered with an electronic eFlow nebulizer system in…
- Trial name
- NCT02951312
- Testing
- Glycopyrrolate Inhalation Solution 25mg, Glycopyrrolate Inhalation Solution 75mg, Glycopyrrolate Inhalation Solution 200mg
- Volunteers
- 12 people
- Sponsor
- Sunovion Respiratory Development Inc.
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Pulmonary Disease, Chronic Obstructive
Absorption & Elimination of Radiolabelled GSK2269557
GSK2269557 is being developed as an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD) and other inflammatory lung diseases such as asthma.
- Trial name
- NCT03315559
- Testing
- [14C]-GSK2269557 IV infusion, GSK2269557 via DPI, [14C]-GSK2269557 oral solution
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
CoronaVirus Induced Disease-2019 (COVID-19)
Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Lung failure is the main cause of death related to COVID-19 infection.
- Trial name
- iNSPIRE (NCT04375397)
- Testing
- Ibrutinib
- Where
- 9 sites in United States
- Volunteers
- 46 people
- Sponsor
- AbbVie
Pulmonary Disease, Chronic Obstructive
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431274
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 239 sites in United States, Argentina and 23 more
- Volunteers
- 2,624 people
- Sponsor
- Boehringer Ingelheim
Refractory and/or Unexplained Chronic Cough
Clinical Study to Evaluate the Efficacy and Safety of Three Different Doses of BAY1817080 Compared to Placebo in Patients With Chronic Cough
Researchers in this study want to find the optimal therapeutic dose of drug BAY1817080 for patients with long-standing cough with or without clear causes (refractory and/or unexplained chronic cough, RUCC).
- Trial name
- PAGANINI (NCT04562155)
- Testing
- BAY1817080
- Where
- 99 sites in United States, Argentina and 17 more
- Volunteers
- 310 people
- Sponsor
- Bayer
Amyotrophic Lateral Sclerosis
Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension
This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan.
- Trial name
- REFALS-ES (NCT03948178)
- Testing
- Levosimendan
- Where
- 79 sites in United States, Australia and 12 more
- Volunteers
- 227 people
- Sponsor
- Orion Corporation, Orion Pharma
Asthma
Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma
This study assessed the efficacy, safety, and pharmacokinetics of indacaterol salts (maleate, xinafoate and acetate) in patients with asthma.
- Trial name
- NCT00927901
- Testing
- Indacaterol maleate 400 μg, Indacaterol acetate 400 μg, Indacaterol xinafoate 400 μg
- Where
- 3 sites in France, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Pharmacokinetics, Epinephrine
Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular Injection and ProAir by Oral Inhalation in Healthy Individuals
To assess the drug exposure profile in systemic circulation of Primatene Mist by inhalation, versus Epinephrine by intramuscular injection, and ProAir HFA by inhalation in healthy adults.
- Conditions
- Pharmacokinetics, Epinephrine, Albuterol, Asthma
- Trial name
- NCT04207840
- Testing
- Epinephrine (0.125 mg/inhalation), Epinephrine Injection Auto-Injector (0.3mg/0.3mL), Albuterol Sulfate (0.09 mg/inhalation)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Pulmonary Disease, Chronic Obstructive
Japan Long-term Safety for Tiotropium Plus Olodaterol
The primary objective of this study is to assess the safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC and olodaterol (delivered by the RESPIMAT Inhaler) in Japanese patients with Chronic…
- Trial name
- NCT01536262
- Testing
- Tiotropium + Olodaterol, Respimat, Olodaterol
- Where
- 24 sites in Japan
- Volunteers
- 122 people
- Sponsor
- Boehringer Ingelheim
Scleroderma, Interstitial Lung Disease
Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma is a rare, long-term autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. Normally, the immune system helps defend the body against disease and infection.
- Trial name
- SLSII (NCT00883129)
- Testing
- Mycophenolate mofetil, Cyclophosphamide
- Where
- 14 sites in United States
- Volunteers
- 142 people
- Sponsor
- Michael Roth
Chronic Obstructive Pulmonary Disease, Lung Disease
Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)
The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.
- Trial name
- NCT01153321
- Testing
- AZD2423
- Where
- Germany
- Volunteers
- 71 people
- Sponsor
- AstraZeneca
Anemia, Sickle Cell
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
People with sickle cell disease (SCD) may develop acute chest syndrome (ACS), which is a common and serious lung condition that usually requires hospitalization.
- Trial name
- NCT00530270
- Testing
- Dexamethasone
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati